A new high performance liquid chromatography method was developed and validated for the quantitation of Cilnidipine and Valsartan in pharmaceutical formulations. Determination was performed using an ODS C18, 250mm x 4.6mm, 5μm column, a mobile phase containing Methanol: Water (85:15) pH 3 adjusts with ortho-phosphoric acid in isocratic flow rate 1.0 mLmin-1. The method was validated with respect to linearity, precision, robustness, and accuracy. The calibration graphs ranged from 1-5 μg/mL in Cilnidipine and 8-40 μg/mL Valsartan Intra-and interday relative standard deviation values for the standard solutions were 0.5%, 1.64% and 0.22%, 1.62 %. Robustness of relative standard deviation values was 0.334, 0.101 respectively. Total recoveries of Cilnidipine and Valsartan from the laboratory prepared mixtures were 98.94 % and 99.04 % respectively.
INTRODUCTION
Genetically Cilnidipine (CLD) (Fig.01A ) chemically, 1,4Dihydrogen -2, 6dimethyl1-4(3nitrophenyl-3,5pyridinecarboxylic acid 2-methoxyethyl (2E)-3-phenyl ester is a dual blocker of L-type of Voltage-gated calcium channel in vascular smooth muscle and N-type of calcium channels in sympathetic nerve terminals that supply blood vessels. Valsartan (VAL) (Fig.01B ) is chemically know as (2S)-3-methyl-2-[N-({4-[2H-1234-tetrazol-5-yl) phenyl] phenyl} methyl) pentanamido] butanoic acid. Valsartan is ARB (Angiotensin receptor blocker) that selectively inhibits the binding of Angiotensin II. To AT1 (Angiotensin Receptor), this is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the AT1-mediated vasoconstrictive and aldosterone onesecreting effective of angiotensine2 and result in a decrease in vascular resistance and blood pressure. [1] [2] [3] [4] [5] [6] [7] [A]
[B] Tablet dosage forms containing Cilnidipine and Valsartan in ratio of 10 mg: 80mg of various brands are available in the market. Cilinidipine has been reported to be determined by HPLC [8] [9] [10] [11] [12] from formulations and in biological fluids. Ratio spectra derivative Spectrophotometry, Valsartan determination has been done by HPLC and the stability indicating assay method. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] However, there is no method available for the simultaneous determination of these two drugs. Therefore, an attempt was made to develop a new, rapid, and sensitive method for the simultaneous determination of Cilnidipine and Valsartan. To access the reproducibility and wide applicability of the developed method, it was validated as per ICH norm, which is mandatory also [27] [28] [29] .
EXPERIMENTAL Materials
Cilnidipine was obtained from J.B.Chemicals and Pharmaceutical Valsartan was kindly gifted by Lupin Laboratories Ltd. Methanol and Acetonitrile HPLC grade was form Merck Laboratories .Water used AR grade. All other reagents used in AR grade.
Instrumentation
The pH of the mobile phase was checked on a microprocessor water proof pH tester (pH tester 20, eutech instruments, oakton, USA). The overall illumination at the point of placement of samples was 6000 lux, which was tested using a calibrated lux meter (Lutron LX-102 digital light meter, Marcucci S.P.A, vignate, Milan). HPLC (Water 600 controller) instrument equipped with a model code 6CE In Line Degasser Af , Reciprocating pump ,Rheodyne 7725i manual injector with a 20μl fixed loop and HPLC syringe of 100μI and with UV-Vis detector. Separation and quantitation were made on ODS C18, and 250 mm x 4.6mm, 5μm column data analyzed by using Data Ace software
Chromatographic Conditions
In Initially to estimate Cilnidipine and Valsartan simultaneously number of mobile phases in different ratios were tried, taking into consideration the system suitability parameters like RT, tailing factor, No. of theoretical plates and HETP, the mobile phase found to be most suitable for analysis was Water (pH3): Methanol in the ratio of (15:85 pH-3 with Orthophosphoric acid). The mobile phase was filtered through 0.45µm Nylon membrane filter paper to remove particulate matter and then degassed by sonication. Flow rate employed for analysis was 1 mLmin-1. Considering the overlay spectra of these two drugs, 245 nm seems to be the most 247 suitable detection wavelength. As at 245 nm is isobestic point of CLD and VAL responses of both drugs fairly well and satisfactorily result (Figure 2 ). 
System Suitability
System suitability parameters such as the number of theoretical plates, HETP and peak tailing are determined. Separation Variable was set and mobile phase was allowed to saturate the column at flow rate 1.0mL/min. After complete saturation of column, six replicates of working standard of CLD (2μg/mL) and VAL (16 μg/mL) were injected. The results obtained are shown in Table 1 . 
Linearity
To establish the linearity of analysis method, a series of dilution ranging from 1-5μg /mL for CLD and 8-40μg/ mL for VAL were prepared. All the solution was filtered through 0.2μm membrane filter and injected, chromatograms were recorded and it was repeated six times. The calibration curve of peak area vs. respective concentration was plotted. A Calibration and regression equation was derived. The results obtained are shown in Table 2 . 
Accuracy
Recovery studies were performed to validate the accuracy of developed method to the preanalyzed sample solution, a definite concentration of standard drug was added to and recovery was studied. Different amount of pure drug solutions was added preanalyzed samples, then solution were analysed. The result of recovery studies and statistical data of CLD and VAL are reported in Table 3 . 
Precision
Five standard dilution was prepared for the repeatability and three replicates where analysed in same day for repeatability, results were found within acceptable limits (R.S.D. %< 2), as shown in Table 3 .
Day to day precision five standard dilution was prepared and three replicates where analysed in different day for intermediate precision and statistically validated. Analyst to Analyst Variation for five standard dilutions was prepared and three replicates where analysed in same day for different analyst for intermediate precision and statistically validated. Although the R.S.D. % value for as shown in Table 4 . 
Robustness
Standard dilution was prepared and three replicates where analysed by Change pH at two levels (± 1). The pH of mobile phase was change 2.9 and 3.1. also change in flow rate (± 1) . The flow rate was change 0.9 min/mL and 1.1 min/mL. Results of the analysis are summarized in Table 5 . 
Tablet Analysis
Contents of CLD and VAL found in the tablets by the proposed method are shown in Table 6 . Twenty tablets were weighed accurately and powdered. A quantity of tablet powder equivalent to 10mg CLD and 80mg VAL was accurately weighted and transferred into a10ml of volumetric flask,7ml of diluent was added. The content was ultrasonicated for 15min. The volume was then diluted to the mark and mixed well. A small portion was withdrawn and filtered through a 0.25μm filter to ensure the absence of particulate matter. The low values of R.S.D. % indicate that the method is precise and accurate. 
CONCLUSIONS
An RP-HPLC method was developed and validated for simultaneous estimation of Cilnidipine and Valsartan in tablet dosage form. The proposed method is fast, accurate, and precise; hence, it can be employed for routine quality control of tablets containing these two drugs in industry.
